Simon Hesse Hoffmann
Director/Board Member at AMBU A/S
Net worth: 32 M $ as of 2024-04-29
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Povl-André Bang Bendz | M | 62 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 10 years |
Tue Østergaard | M | 47 |
HC Andersen Capital ApS
HC Andersen Capital ApS MiscellaneousMiscellaneous HC Andersen Capital ApS functions as an investment holding Danish company. The private company is based in Copenhagen, Denmark. The company was founded in 2020. Tue Østergaard has been the CEO of the company since 2020. | 4 years |
Jørgen Drejer | M | 69 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 7 years |
Anita Krarup Rasmussen | F | 49 | 11 years | |
Ole Thastrup | M | 71 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 18 years |
Camilla Huse Bondesson | M | 66 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 5 years |
Ulrich Karl Walter Spengler | M | 57 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 11 years |
Michael del Prado | M | - | 3 years | |
Thomas Lars Andresen | M | - |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | 12 years |
Shacey Petrovic | F | 50 | 2 years | |
Britt Meelby Jensen | F | 51 | 5 years | |
Henrik Ehlers Wulff | M | 54 | 9 years | |
Christian Sagild | M | 64 | 12 years | |
Tabea Sturmheti | M | 39 | 7 years | |
Grith Hagel | F | 65 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 18 years |
Jørgen Jensen | M | 56 | 4 years | |
Susanne Larsson | F | 56 | 3 years | |
Charlotte Elgaard Bjørnhof | F | - | 3 years | |
Michael Mortensen | M | - |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | - |
Fernando Andreu | M | 60 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 3 years |
Sten Hornsleth | M | - |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | 5 years |
Jesper Bartroff Frederiksen | M | - | 3 years | |
Thomas Bachgaard Jensen | M | - | 3 years | |
Henrik Skak Bender | M | 40 | - | |
Finn Möhring | M | - | 1 years | |
Henrik Birk | M | 50 | 1 years | |
John Gordon McVie | M | - |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | - |
Anders Hjort | M | - | - | |
Torsten Jepsen | M | - |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | - |
Rasmus Irming Jølck | M | - |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | - |
Kenneth Graabek Johansen | M | 48 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 3 years |
Michael Schaefer | M | - |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 2 years |
Michael Lutz | M | 56 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 4 years |
Jesper B. Boysen | M | 64 |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | - |
Hanne Leth Hillman | F | 59 |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | 7 years |
Steffen Peter Anker Heegaard | M | 65 |
HC Andersen Capital ApS
HC Andersen Capital ApS MiscellaneousMiscellaneous HC Andersen Capital ApS functions as an investment holding Danish company. The private company is based in Copenhagen, Denmark. The company was founded in 2020. Tue Østergaard has been the CEO of the company since 2020. | - |
Nils Aage Brünner | M | 72 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 4 years |
Jesper Roested | M | - |
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | - |
Sanne Kjaersgaard Hjordrup | F | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Højgaard | M | 60 | 9 years | |
Juan Farré | M | 59 |
2cureX ApS
2cureX ApS Pharmaceuticals: MajorHealth Technology 2cureX ApS develops and manufactures drugs and technology for the treatment of cancer. Its ChemoCellomics, integrates synthesis of compound libraries with throughput screening (HTS) in primary cells from patients. The company was founded by Ole Thastrup, Timm Jessen, and Grith Hagel in 2006 and is headquartered in Birkerod, Denmark. | 2 years |
Mikkel Trier Wagner | M | - | 15 years | |
Måns Eskil Barsne | M | - | 8 years | |
Maarten van der Linden | M | 55 | 4 years | |
Juan-José Gonzalez | M | 52 | 3 years | |
Carit Jacques Andersen | M | 60 | 2 years | |
Henrik Ankjær | M | - | 5 years | |
Thomas Schmidt | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
Denmark | 45 | 93.75% |
Sweden | 8 | 16.67% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Simon Hesse Hoffmann
- Personal Network